A detailed history of Baker Bros. Advisors LP transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 1,086,115 shares of MRSN stock, worth $2.41 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,086,115
Previous 1,086,115 -0.0%
Holding current value
$2.41 Million
Previous $2.18 Million 6.0%
% of portfolio
0.02%
Previous 0.03%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$3.08 - $9.55 $2.46 Million - $7.64 Million
-800,000 Reduced 42.42%
1,086,115 $3.57 Million
Q1 2023

May 15, 2023

BUY
$4.0 - $7.02 $7.54 Million - $13.2 Million
1,886,115 New
1,886,115 $7.75 Million

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $216M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.